Choose AOD-9604 Vial Size — Dosing Protocol Guide

Researchers ordering AOD-9604 for the first time consistently make the same purchasing error: they choose a vial size based on price per milligram without calculating actual protocol consumption. A 5mg vial costs less per unit than two 2mg vials. But if your daily dose is 200mcg and post-reconstitution stability is 28 days, you'll discard 2.4mg of unused peptide when the vial expires. The correct vial size isn't the cheapest upfront cost. It's the size that matches your exact dosing window without waste.

We've guided hundreds of research teams through peptide procurement. The gap between ordering efficiently and wasting budget comes down to three calculations most protocols never document upfront.

How do you choose the right AOD-9604 vial size for your research protocol?

Choose AOD-9604 vial size by multiplying daily dose (typically 200–300mcg) by protocol duration in days, then matching that total to the nearest vial size without exceeding 28-day post-reconstitution stability. A 2mg vial supports 10 days at 200mcg daily; a 5mg vial supports 25 days. Reconstitute only what you'll use within the bacteriostatic water stability window to prevent peptide degradation.

The featured snippet answers the mechanical question. But it skips the critical constraint that determines whether your vial size choice actually works in practice. AOD-9604 degrades measurably after 28 days in bacteriostatic water at 2–8°C, regardless of how much peptide remains in the vial. This means vial size selection isn't just math. It's timed inventory management. This article covers the dosing variables that determine consumption rate, the reconstitution math that sets your deadline, and the procurement mistakes that waste peptide before you've completed a single protocol cycle.

Daily Dose and Injection Frequency Determine Consumption Rate

AOD-9604 protocols in metabolic research settings typically run 200–300mcg per day, administered as a single subcutaneous injection. At 200mcg daily, a 2mg vial delivers exactly 10 days of dosing. At 300mcg daily, that same 2mg vial covers 6.7 days. Not enough to complete a full week without starting a second vial mid-protocol.

The half-life of AOD-9604 is approximately 2 hours in circulation, which is why most protocols dose once daily rather than splitting into multiple injections. There's no pharmacokinetic advantage to dividing a 200mcg dose into two 100mcg injections 12 hours apart. The peptide clears the system within 8–10 hours regardless. Daily dosing keeps the protocol simple and the consumption math clean.

Our team has found that researchers often round their vial size up 'just in case'. Ordering a 5mg vial for a 14-day protocol that only requires 2.8mg total. The extra peptide sits in the vial past the 28-day stability window and gets discarded. The correct approach: calculate total protocol demand (daily dose × number of days), add a 10% buffer for draw loss and measurement error, then order the vial size closest to that adjusted total. For a 200mcg daily protocol running 20 days, that's 4mg needed + 400mcg buffer = 4.4mg total, which maps to a 5mg vial with minimal waste.

One variable most guides ignore: draw loss compounds over time. Each time you insert a needle into the vial to draw a dose, 5–10mcg of solution adheres to the needle hub and syringe dead space. Over 20 injections, that's 100–200mcg of peptide you paid for but never injected. This is why the 10% buffer exists. It accounts for mechanical loss, not dosing error.

Reconstitution Volume and Stability Set Your Deadline

AOD-9604 arrives as lyophilized powder and requires reconstitution with bacteriostatic water before use. The volume of bacteriostatic water you add determines concentration. Which determines how much liquid you draw per dose. But it doesn't change total peptide content. A 2mg vial reconstituted in 1mL yields 2mg/mL; the same vial in 2mL yields 1mg/mL. Both contain 2mg total.

Concentration matters for injection volume comfort. Drawing 0.1mL (100 microliters) per dose is standard for subcutaneous injections. It's a small enough volume to inject quickly with minimal site irritation. At 2mg/mL concentration, 0.1mL delivers 200mcg. At 1mg/mL, you'd need to draw 0.2mL to get the same 200mcg dose. Both work, but higher concentrations allow smaller injection volumes.

The critical constraint: bacteriostatic water maintains peptide stability for 28 days at 2–8°C after reconstitution. After 28 days, oxidation and hydrolysis begin degrading the peptide backbone even under refrigeration. This isn't a 'maybe' or 'it depends'. The 28-day window is the hard limit established by stability assays on reconstituted peptides stored in sealed vials under ideal conditions. Room temperature shortens that to 48–72 hours. Freezing reconstituted peptide is not recommended. Ice crystal formation disrupts the tertiary structure.

Here's what this means for vial size selection: if you're running a 30-day protocol at 200mcg daily, you need 6mg total. A single 5mg vial won't cover it, and a 10mg vial will expire before you've used half. The correct procurement: one 5mg vial (covers days 1–25) and one 2mg vial (covers days 26–30). Reconstitute the 5mg vial on day 1 and the 2mg vial on day 26. This keeps all peptide within the stability window without waste.

Procurement Strategy for Multi-Week Protocols

Longer protocols introduce a timing problem: you can't reconstitute all your peptide upfront because it'll degrade before you finish the protocol. The solution isn't ordering one massive vial. It's staging your reconstitution across multiple smaller vials timed to the 28-day window.

For a 60-day protocol at 200mcg daily, you need 12mg total. The optimal procurement: two 5mg vials and one 2mg vial. Reconstitute vial 1 (5mg) on day 1. It covers days 1–25. Reconstitute vial 2 (5mg) on day 26. It covers days 26–50. Reconstitute vial 3 (2mg) on day 51. It covers days 51–60. Every dose falls within the stability window, and total waste is under 5%.

Compare that to ordering a single 15mg vial and reconstituting it all at once. By day 28, you've used 5.6mg and have 9.4mg remaining. All of which is now past the stability threshold. You'd discard more than 60% of the peptide you paid for.

Our experience working with research teams across peptide procurement: the most common mistake isn't miscalculating total need. It's failing to map reconstitution timing before ordering. Researchers see the per-mg savings on bulk vials and assume they can 'make it work' by freezing portions or extending refrigerated storage. Neither works. Peptide degradation is enzymatic and irreversible once initiated.

The second-most-common mistake: ordering vial sizes that don't align with bacteriostatic water bottle volumes. Bacteriostatic water typically comes in 10mL or 30mL bottles. If you're reconstituting multiple 5mg vials over a 60-day protocol, you'll need at least one 30mL bottle to cover all reconstitutions. Running out of bacteriostatic water mid-protocol and substituting sterile water (which lacks the benzyl alcohol preservative) collapses your stability window to under 48 hours. Plan your bacteriostatic water supply when you plan vial sizes.

AOD-9604 Vial Size Comparison

What If: AOD-9604 Vial Size Scenarios

What If I'm Running a 14-Day Pilot Study at 200mcg Daily?

Order one 5mg vial. Your total consumption is 2.8mg (14 days × 200mcg), which leaves 2.2mg unused. But reconstituting a 2mg vial plus half of a second vial creates more waste and doubles your bacteriostatic water use. The 5mg vial stays within the 28-day window and gives you flexibility if you extend the pilot by a few days without needing to order mid-study.

What If I Want to Dose 300mcg Daily for 20 Days?

Order one 5mg vial and one 2mg vial. Total demand is 6mg (20 days × 300mcg). Reconstitute the 5mg vial on day 1 (covers days 1–16 at 300mcg daily) and the 2mg vial on day 17 (covers days 17–20 with 400mcg remaining as buffer). This approach keeps both vials within stability and avoids the pricing inefficiency of ordering three 2mg vials.

What If My Protocol Runs 45 Days at 200mcg Daily?

Order two 5mg vials. Reconstitute vial 1 on day 1 (covers days 1–25) and vial 2 on day 26 (covers days 26–45 with 1mg buffer remaining). Do not reconstitute both vials at the start. The second vial will degrade before you reach day 26. Staged reconstitution is the only way to prevent waste on protocols exceeding 28 days.

The Unforgiving Truth About AOD-9604 Vial Size Selection

Here's the honest answer: most researchers over-order because they've been conditioned by consumer supplement pricing where 'more is better' and expiration dates are theoretical. Peptides don't work that way. A 10mg vial isn't 'insurance' against running out. It's a guarantee you'll throw away 40–60% of what you paid for unless you're running concurrent protocols or have a team large enough to consume it within 28 days post-reconstitution.

The peptide suppliers who push bulk vials as 'better value' are technically correct on per-milligram cost. But they're not accounting for stability-driven waste, which is the actual cost that matters. A 5mg vial at $180 that you use completely is cheaper than a 10mg vial at $280 where you discard half. The real pricing question isn't 'what's the per-mg rate'. It's 'what's the per-usable-mg rate after accounting for degradation.'

If your protocol timeline is uncertain, order conservatively. Start with a 2mg or 5mg vial, run the first cycle, then order additional vials based on actual consumption. The two-day shipping delay between cycles is operationally insignificant compared to the cost of pre-ordering peptide you can't use before it degrades. This isn't a failure of planning. It's disciplined inventory management for time-sensitive biologics.

Reconstituted AOD-9604 doesn't have a grace period. At 28 days, oxidation is measurable. By day 35, potency loss is significant. By day 42, you're injecting degraded fragments that no longer bind to the target receptor. Extending 'just a few more days' because the vial still has liquid in it wastes the entire remaining volume. And the preceding weeks of data if you're running a controlled study. When the vial hits 28 days, you discard it. No exceptions.

Understand this upfront and the vial size question becomes straightforward. Calculate total protocol demand. Add 10% for draw loss. Match that number to the vial size that gets you closest without exceeding 28 days post-reconstitution. If your protocol is longer than 28 days, split it across multiple vials reconstituted in sequence. That's the entire decision framework. No shortcuts, no 'it depends,' no hoping refrigeration buys you extra time. It doesn't.

You can explore our full range of research-grade peptides to find compounds that align with your protocol requirements. Each peptide in our catalog undergoes the same small-batch synthesis process with verified amino-acid sequencing. The quality standard that makes vial size planning reliable in the first place.

Choose AOD-9604 vial size by working backward from your deadline. Not forward from your budget. The math is unforgiving, but it's also simple: if the peptide degrades before you use it, the per-mg savings you thought you captured never existed.